|
06/18/09 |
Novartis:
New biological therapy Ilaris® approved in US to treat
children and adults with CAPS, a serious life-long auto-inflammatory
disease |
|
|
|
|
06/12/09 |
Novartis successfully demonstrates capabilities of
cell-based technology for production of A(H1N1) vaccine |
|
|
|
|
|
Merck Statement in Response to the FDA's June 12, 2009
Communication with Updated Information on Leukotriene Inhibitors,
Including SINGULAIR® (montelukast sodium) |
|
|
|
|
06/10/09 |
Bristol-Myers Squibb Announces Dividend |
|
|
|
|
06/08/09 |
GSK and Shenzhen Neptunus create new alliance to develop
and manufacture influenza vaccines in China |
|
|
|
|
06/05/09 |
Novartis:
Tasigna® shows rapid and deep responses in newly
diagnosed patients with a form of chronic myeloid leukemia |
|
|
|
|
06/01/09 |
Thermo Fisher Scientific Reinforces its Leadership in
Mass Spectrometry at ASMS |
|
|
|
|
05/26/09 |
Novartis to enter Japan vaccines market through agreement
for Haemophilus Influenzae Type B (Hib) vaccine |
|
|
|
|
|
BMS:
FDA Grants Full Approval for SPRYCEL® (dasatinib) for the
Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or
Intolerant to Prior Therapies Including Gleevec®* |
|
|
|
|
|
Applied Biosystems Introduces Two New Lines of Capillary
Electrophoresis Genetic Analyzers |
|
|
|
|
05/25/09 |
Roche:
Two-year data reinforce effectiveness of ACTEMRA in
inhibiting joint damage and improving physical function in patients with
rheumatoid arthritis |
|
|
|
|
05/22/09 |
US Department of Health and Human Services (HHS)
purchases GSK’s A (H1N1) influenza antigen and proprietary adjuvant
system |
|
|
|
|
05/21/09 |
Lilly Advances Second Alzheimer's Disease Treatment
Candidate Into Late-Stage Testing by Launching Two Global Trials
|
|
|
|
|
05/19/09 |
Genentech and Biogen Idec Submit Applications to the FDA
for Rituxan for Most Common Type of Adult Leukemia
|
|
|
|
|
05/15/09 |
GlaxoSmithKline update: A (H1N1) influenza vaccine
development |
|
|
|
|
05/14/09 |
|
|
|
|
|
05/12/09 |
CV Therapeutics' Board of Directors Rejects Astellas'
Tender Offer |
|
|
|
|
05/08/09 |
GSK:
New data for GlaxoSmithKline’s vaccine, Cervarix®,
presented at IPV Conference |
|
|
|
|
05/06/09 |
Novartis:
Glivec® approved in EU as first post-surgery therapy to
reduce risk of cancer returning in patients with aggressive
gastrointestinal tumors |
|
|
|
|
05/05/09 |
Roche: Important New Treatment Option Approved in US for
Patients with the Most Aggressive Form of Brain Cancer |
|
|
|
|
|
Genentech:
FDA Grants Accelerated Approval of Avastin for Brain
Cancer (Glioblastoma) That Has Progressed Following Prior Therapy |
|
|
|
|
04/23/09 |
Thermo Fisher Scientific Reports 2009 First Quarter
Results; Updates Guidance for 2009 |
|
|
|
|
|
|
|
|
|
|
04/22/09 |
Roche:
Phase III C-08 study of Avastin in early-stage colon
cancer does not meet primary endpoint |
|
|
|
|
04/16/09 |
Biogen Idec Receives Approval for TYSABRI® High Titer
Production |
|
|
|
|
04/13/09 |
Merck Statement in Response to the FDA's Update Regarding
a Safety Review of SINGULAIR® (montelukast) |
|
|
|
|
04/12/09 |
CV Therapeutics' Board of Directors Rejects Astellas'
Tender Offer |
|
|
|
|
04/08/09 |
Novartis:
Coartem® receives FDA approval becoming first artemisinin-based
combination treatment (ACT) for malaria in the US |
|
|
|
|
|
Myriad Pharmaceuticals Receives IND Approval for New
Cancer Drug |
|
|
|
|
|
Nature Publishes Pre-Clinical Data On An Inhibitor Of A
Novel Target Discovered By Millennium |
|
|
|
|
|
Genentech Announces Voluntary Withdrawal of Raptiva from
the U.S. Market |
|
|
|
|
|
Lilly:
Newly Published Phase III Study Shows Arzoxifene
Significantly Increased Bone Mineral Density
|
|
|
|
|
04/03/09 |
Thermo Fisher Scientific Testing Method Approved For
Detecting Salmonella in Food |
|
|
|
|
04/02/09 |
Novartis:Ixiaro®
vaccine receives Marketing Authorization in Europe for the prevention of
Japanese Encephalitis |
|
|
|
|
|
Vermillion, Inc. Files a Voluntary Petition for
Reorganization Relief Under Chapter 11 of the United States Bankruptcy
Code |
|
|
|
|
04/01/09 |
GSK submits Tyverb®/Tykerb® (lapatinib) for first-line
treatment of metastatic breast cancer in Europe, US |
|
|
|
|
03/31/09 |
Bayer HealthCare and Genzyme Corporation Enter New
Strategic Agreement |
|
|
|
|
03/26/09 |
Roche completes acquisition of Genentech |
|
|
|
|
03/23/09 |
FDA Approves Symbyax(R) as First Medication for
Treatment-Resistant Depression |
|
|
|
|
03/19/09 |
Novartis:
Glivec® recommended for use in Europe as first
post-surgery treatment for gastrointestinal stromal tumors (GIST) |
|
|
|
|
|
GlaxoSmithKline announces sale of shares in Quest
Diagnostics Inc. |
|
|
|
|
03/18/09 |
Roche:
Herceptin now shown to significantly prolong the lives of
patients with HER2-positive advanced stomach cancer |
|
|
|
|
|
Novartis:
Glivec® substantially reduces risk of cancer returning in
patients with life-threatening gastrointestinal stromal tumors, The
Lancet reports |
|
|
|
|
|
Genetech:
OSI Pharmaceuticals Submits Supplemental New Drug
Application to the FDA for Tarceva as a First-Line Maintenance Therapy
in Advanced Non-Small Cell Lung Cancer |
|
|
|
|
|
FDA Accepts Amgen's Submission and Files Biologics
License Application for Denosumab
|
|
|
|
|
03/11/09 |
Biogen Idec:
Phase III Study of Rituxan in Lupus Nephritis Did Not
Meet Primary Endpoint |
|
|
|
|
03/10/09 |
Roche Annual General Meeting: dividend raised by 9
percent |
|
|
|
|
03/09/09 |
Thermo Fisher Scientific Expands its Industry-Leading
Portfolio at PITTCON 2009 |
|
|
|
|
|
Roche-Genentech deal called close
(linked to SFGate) |
|
|
|
|
|
Drugmaker merger: Merck to buy Schering-Plough
(linked to SFGate)
|
|
|
|
|
|
Lilly Granted Temporary Restraining Order to Halt Launch
of Generic Raloxifene |
|
|
|
|
|
MS Patients Treated with TYSABRI® Remain Free of Disease
Activity for Two Years, According to Data Published in
The Lancet Neurology |
|
|
|
|
03/04/09 |
GSK:NICE
refuses funding for advanced breast cancer treatment, Tyverb® (lapatinib) |
|
|
|
|
03/03/09 |
Millennium Initiates Two Phase Il Trials Of Novel Aurora
A Kinase Inhibitor |
|
|
|
|
03/02/09 |
ImClone Systems and Bristol-Myers Squibb Update Status of
First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental
Biologics Application for ERBITUX®in U.S.
|
|
|
|
|
02/27/09 |
Bayer proposes increased dividend for 2008 of EUR 1.40
per share
Plans to switch from bearer shares to registered shares |
|
|
|
|
02/24/09 |
Myriad Genetics Announces 2-for-1 Stock Split |
|
|
|
|
|
Novartis shareholders approve 25% dividend increase at
2009 Annual General Meeting |
|
|
|
|
|
Genentech Receives Final Notification Upholding Cabilly
Patent in Reexamination Proceeding |
|
|
|
|
02/23/09 |
Genentech Special Committee Rejects Roche's $86.50 Offer
as Inadequate |
|
|
|
|
|
European Commission Approves EFIENT(R) (prasugrel) for
Patients with Acute Coronary Syndrome Undergoing PCI
|
|
|
|
|
02/19/09 |
MDS Analytical Technologies Announces Validation of Two
More Kits for High-Throughput Detection of Melamine in Food |
|
|
|
|
|
National Coalition for Cancer Survivorship, UCLA,
Wellpoint, and Genentech Launch Initiative to Provide Coordinated
Follow-Up Care for People Surviving Cancer
|
|
|
|
|
02/18/09 |
Amgen:
FDA Accepts Amgen's Submission and Files Biologics
License Application for Denosumab
|
|
|
|
|
02/17/09 |
GSK initiates phase III programme for novel type 2
diabetes medication, Syncria® (albiglutide) |
|
|
|
|
02/12/09 |
Novartis gains worldwide rights to elinogrel, a Phase II
anti-clotting compound with potential to reduce risk of heart attack and
stroke |
|
|
|
|
|
Bayer Schering Pharma to invest 100 million Euro in China
to build a global R&D center |
|
|
|
|
02/09/09 |
Roche commences tender offer for Genentech for US$86.50
per share in cash
|
|
|
|
|
|
MS Patients Treated with TYSABRI® Remain Free of Disease
Activity for Two Years, According to Data Published in
The Lancet Neurology |
|
|
|
|
02/06/09 |
GlaxoSmithKline and Idenix Pharmaceuticals sign worldwide
license agreement for IDX899, a novel NNRTI for the treatment of HIV |
|
|
|
|
|
Amgen:
Nplate(R) Approved in the European Union for the
Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
|
|
|
|
|
01/27/09 |
Novartis and Medicines for Malaria Venture launch Coartem®
Dispersible, the first ACT* developed for children suffering from
malaria
|
|
|
|
|
01/26/09 |
Thermo Fisher Among Top-10 Fastest Growing Companies in
China
|
|
|
|
|
01/23/09 |
Geron Receives FDA Clearance to Begin World's First Human
Clinical Trial of Embryonic Stem Cell-Based Therapy
|
|
|
|
|
|
ImClone Systems and Bristol-Myers Squibb Update the
Status of Non-Small Cell Lung Cancer Supplemental Biologics Application
Submission for ERBITUX®
|
|
|
|
|
01/22/09 |
Novartis launches Extavia®, a new therapeutic option to
help patients combat devastating symptoms of multiple sclerosis |
|
|
|
|
|
GeneBio and Utrecht University Announce Collaborative
Partnership Around Phenyx |
|
|
|
|
01/21/09 |
Genentech Announces Vice President Appointment in
Research
|
|
|
|
|
|
Myriad Pharmaceuticals Acquires Novel HIV Drug, Bevirimat
|
|
|
|
|
|
Invitrogen Launches Benchtop Device That Simplifies
Protein Analysis Workflows
|
|
|
|
|
01/13/09 |
Merck Statement in Response to the FDA's Update Regarding
a Safety Review of SINGULAIR® (montelukast)
|
|
|
|
|
12/31/08 |
|
|
|
|
|
12/20/08 |
Novartis:
Glivec receives US approval as first treatment to reduce
risk of cancer returning in patients with gastrointestinal stromal
tumors |
|
|
|
|
12/18/08 |
Genentech:
Phase III Study Showed Rituxan® Decreased The
Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis
(RA) |
|
|
|
|
|
Bristol-Myers Squibb Announces Dividend |
|
|
|
|
12/17/08 |
Abbott Exercises Its Option to Acquire IBIS Biosciences,
a Subsidiary of ISIS |
|
|
|
|
12/16/08 |
Amgen:Oncology
Biomarker KRAS to be Discussed at FDA Panel Meeting
|
|
|
|
|
12/15/08 |
Medarex to Receive Milestone Payment for Approval of
STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque
Psoriasis |
|
|
|
|
12/13/08 |
Novartis:Afinitor®
shows potential to reverse resistance to Herceptin®[*] in metastatic
breast cancer patients, leading to Phase III trial |
|
|
|
|
12/08/08 |
Thermo Fisher Scientific Opens Major Clinical Services
Facility in India |
|
|
|
|
|
Medarex Announces Enhanced Activity Data with Second
Generation Anti-CD30 Antibody for Malignant Lymphoma |
|
|
|
|
|
Geron Presents Interim Clinical Data On Its Telomerase
Inhibitor Drug Trial In Patients With Multiple Myeloma
|
|
|
|
|
12/06/08 |
Rituxan in Combination with Chemotherapy Improves
Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer |
|
|
|
|
12/03/08 |
Geron Announces Initiation of Phase I Clinical Trial of
Vaccine Candidate Targeting Telomerase by MERCK & Co., Inc.
|
|
|
|
|
12/02/08 |
Thermo Fisher Scientific Launches Program to Meet
Melamine Detection Challenges |
|
|
|
|
11/26/08 |
Life Technologies Announces Final Results of Election
Regarding Invitrogen and Applied Biosystems Merger Consideration |
|
|
|
|
11/25/08 |
Roche signs definitive agreement to acquire Memory
Pharmaceuticals |
|
|
|
|
11/23/08 |
Genentech:
Avastin Plus Commonly Used Chemotherapies Demonstrated
Improved Progression-Free Survival In Advanced Breast Cancer |
|
|
|
|
11/21/08 |
Novartis:
Rasilez HCT® receives recommendation for European
approval as a single-pill combination to treat high blood pressure |
|
|
|
|
|
Invitrogen and Applied Biosystems Complete Merger |
|
|
|
|
11/18/08 |
Millenium:
New Data Will Be Presented At Ash On Velcade® (Bortezomib)
For Injection-Based Therapies In Multiple Myeloma And Non-Hodgkin’s
Lymphoma |
|
|
|
|
11/11/08 |
Thermo Fisher Scientific Strengthens Anatomical Pathology
Portfolio with Acquisition of Raymond A. Lamb |
|
|
|
|
11/06/08 |
CVT:FDA
Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims
for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial
Fibrillation and HbA1c |
|
|
|
|
11/05/08 |
Medarex Receives Milestone Payment for Investigational
Antibody Targeting Integrin Receptors |
|
|
|
|
11/04/08 |
Thermo Fisher Scientific to Collaborate with Genentech on
Novel Technology Enabling Development of siRNA Therapeutics |
|
|
|
|
11/03/08 |
Genentech Submits Application to U.S. Food and Drug
Administration for Avastin in the Most Aggressive Form of Brain Cancer |
|
|
|
|
10/30/08 |
Biogen Idec Elects to Participate with Genentech in the
Development and Commercialization of a Next Generation Anti-CD20
Molecule |
|
|
|
|
10/28/08 |
GeneBio and Proxeon Sign Agreement for Phenyx and
ProteinCenter |
|
|
|
|
|
Medarex And PharmAthene Announce New Therapeutic Data for
Anthrax Anti-Toxin, Valortim(R) |
|
|
|
|
|
Geron Scientists and Collaborators Demonstrate Activity
of Pancreatic Islet-like Cells Derived from Human Embryonic Stem Cells
in Diabetes |
|
|
|
|
10/27/08 |
|
|
|
|
|
|
Amgen:
Enbrel(R) (etanercept) Is the First Biologic With
Published Efficacy and Safety Data for up to a Decade of Continuous Use
for the Treatment of Moderate to Severe Rheumatoid Arthritis
|
|
|
|
|
10/26/08 |
CuraGen Corporation Receives Notification from NASDAQ |
|
|
|
|
|
Merck:
New Phase III Study in Previously Untreated HIV Patients
Showed Merck's ISENTRESS® (raltegravir) Reduced HIV Viral Load to
Undetectable Levels, Comparable to Efavirenz, When Taken in Combination
with Other Medicines |
|
|
|
|
10/21/08 |
|
|
|
|
|
10/09/08 |
Invitrogen Announces Completion of
Detailed Integration Plans Relating to Applied Biosystems Combination |
|
|
|
|
10/07/08 |
Thermo
Fisher Scientific LC-MS/MS Solution Used to Detect Melamine |
|
|
|
|
10/06/08 |
Phase III Study Showed Rituxan in Combination with
Chemotherapy Improved Progression-Free Survival in Patients with
Relapsed Chronic Lymphocytic Leukemia |
|
|
|
|
10/03/08 |
Genentech, Glycart and Roche enter into collaboration
agreement for potential cancer therapy
|
|
|
|
|
09/29/08 |
U.S. Food and Drug Administration Selects Applied
Biosystems to Provide Mass Spectrometry Instrument Systems for Food
Contaminant Testing |
|
|
|
|
09/28/08 |
SIB announces first mapping of all human proteins (pdf file) |
|
|
|
|
09/26/08 |
Invitrogen Completes Syndication of Financing for Applied
Biosystems Acquisition |
|
|
|
|
|
CuraGen Corporation Receives Notification from NASDAQ |
|
|
|
|
09/22/08 |
Thermo Fisher Scientific Demonstrates Leading
Technologies for Food Safety at AOAC |
|
|
|
|
|
BMS:
ERBITUX®
Five-Year Data Show Significant Improvement in Overall Survival for
Patients with Locally or Regionally Advanced Head and Neck Cancer |
|
|
|
|
09/17/08 |
Millennium Hires Two Senior Executives |
|
|
|
|
09/16/08 |
GeneBio Launches
SmileMS 0.9 at Swiss MedLab International Congress
|
|
|
|
|
09/15/08 |
Medarex:
Updated Survival Data from Three Phase 2 Ipilimumab
Studies Showed Almost Half of Previously Treated Metastatic Melanoma
Patients Alive Beyond One Year |
|
|
|
|
09/12/08 |
FDA Approves Merck's GARDASIL® to Protect Against Two
Additional Cancers |
|
|
|
|
09/02/08 |
GlaxoSmithKline’s darapladib modifies coronary plaque
composition and lowers Lp-PLA2 activity, a biomarker predictive of heart
attack risk |
|
|
|
|
08/29/08 |
Novartis decides not to pursue further development of
Aurograb(TM) |
|
|
|
|
08/28/08 |
Agilent expert discusses methods for detecting arsenic in
drinking water |
|
|
|
|
08/27/08 |
Novartis,
Glivec receives FDA priority review as first therapy to
reduce recurrence of gastrointestinal stromal tumors after surgery |
|
|
|
|
08/25/08 |
Invitrogen Sets Date for Special Meeting of Shareholders
to Vote on Proposed Merger with Applied Biosystems |
|
|
|
|
|
Applied Biosystems Sets Date for Special Meeting of
Shareholders to Vote on Proposed Merger with Invitrogen Corporation |
|
|
|
|
08/18/08 |
GeneBio’s Expanded
Phenyx Platform Debuts at HUPO 2008 |
|
|
|
|
08/12/08 |
Geron and Exeter Life Sciences Merge Start Licensing and
Viagen To Form Combined Licensing and Operating Company for Animal
Cloning Technologies |
|
|
|
|
|
Sloan-Kettering
Institute to Use GeneBio’s Phenyx Protein ID Platform |
|
|
|
|
08/07/08 |
Geron Initiates Clinical Trial of GRN163L in Combination
with Paclitaxel and Bevacizumab in Patients with Breast Cancer
|
|
|
|
|
08/06/08 |
Incyte Announces Closing of Public Offering of Common
Stock |
|
|
|
|
07/30/08 |
Roche:
FDA
Advisory Committee recommends approval of Actemra for the treatment of
rheumatoid arthritis |
|
|
|
|
|
Lilly:
Phase II Data on Lilly's Antibody Show It Affects Amyloid
Beta, a Protein Believed To Be Associated with Alzheimer's Disease |
|
|
|
|
07/28/08 |
Novartis:
Exforge® helps nearly twice as many patients control
their high blood pressure compared to amlodipine alone
|
|
|
|
|
07/25/08 |
Thermo Fisher Scientific Acquires FIBERLite Centrifuge,
Inc. |
|
|
|
|
|
GlaxoSmithKline and the Harvard Stem Cell Institute
announce a unique collaboration to enable the discovery of new medicines |
|
|
|
|
07/24/08 |
Genentech Forms Special Committee of Independent
Directors to Review Roche Proposal |
|
|
|
|
07/23/08 |
Roche
starts acquisition process of ARIUS to gain access to new screening
platform for antibody therapeutics |
|
|
|
|
07/22/08 |
Roche
acquires Mirus to advance research in the field of RNAi delivery |
|
|
|
|
|
Biogen Idec and Elan Celebrate Second Anniversary of
TYSABRI® for the Treatment of Multiple Sclerosis |
|
|
|
|
07/21/08 |
Thermo
Fisher Scientific Mass Spectrometry Instruments Used by Harvard
University to Identify Proteins in Dinosaur Fossils and Cancer Pathways |
|
|
|
|
|
Swiss drugmaker Roche bids to buy Genentech
Bernadette
Tansey, San Francisco Chronicle, 07/21/08 Swiss drugmaker Roche stunned
executives of Genentech Inc. on Monday with a $43.7 billion offer to
acquire full control of the biotechnology powerhouse, a move that would
make a private subsidiary of a Bay Area company that has dominated the
industry for... |
|
|
|
|
07/18/08 |
|
|
|
|
|
|
MDS To Record Restructuring Charge |
|
|
|
|
|
|
|
|
|
|
07/17/08 |
Thermo Fisher Scientific Acquires Affinity BioReagents |
|
|
|
|
|
Novartis gains momentum with strong performance in first
half of 2008 from portfolio focused on growth areas of healthcare |
|
|
|
|
07/16/08 |
Abbott Reports Stronger-than-Expected Sales and Earnings
Growth in Second Quarter and Raises Full-Year Outlook
|
|
|
|
|
07/14/08 |
Genentech Announces Second Quarter 2008 Results |
|
|
|
|
07/11/08 |
Novartis enters strategic partnership with Lonza to
accelerate growth of biologics pipeline |
|
|
|
|
|
Genentech Settles Dispute Related To Cabilly Patent
|
|
|
|
|
07/10/08 |
Novartis buys additional 51.7% stake in Speedel and
announces plans to acquire remaining shares in a mandatory public tender
offer |
|
|
|
|
07/08/08 |
Novartis completes acquisition of 25% stake in Alcon from
Nestlé, first step toward majority ownership of the world leader in eye
care |
|
|
|
|
|
Merck Responds to Questions about Adverse Events Reported
following Vaccination with GARDASIL® |
|
|
|
|
07/02/08 |
FDA Approves Abbott's XIENCE™ V Drug Eluting Stent
|
|
|
|
|
07/01/08 |
Thermo Fisher Scientific Acquires Open Biosystems,
Creating Unmatched RNAi Platform |
|
|
|
|
|
|
|
|
|
|
|
Applera Corporation Completes Separation of its Celera
Business and is Renamed Applied Biosystems Inc. |
|
|
|
|
06/30/08 |
Myriad Genetics Reports Results of U.S. Phase 3 Trial of Flurizan™ in
Alzheimer's Disease |
|
|
|
|
06/26/08 |
European approval for Roche`s Pegasys personalises treatment for a
subgroup of hepatitis C patients: chance for cure with only four months
of treatment |
|
|
|
|
|
Bristol-Myers Squibb Completes Acquisition of Kosan Biosciences
Incorporated |
|
|
|
|
06/18/08 |
Cervarix™, GSK’s cervical cancer vaccine, wins tender for
UK national immunisation programme |
|
|
|
|
|
Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Review
Period for Acquisition of Kosan Biosciences Incorporated |
|
|
|
|
06/17/08 |
Novartis:Rasilez®
ASPIRE HIGHER clinical program expands to 35,000 patients in 14 trials,
the largest cardio-renal outcomes program ever |
|
|
|
|
06/16/08 |
Lilly:
FDA Approves Cymbalta® for the Management of Fibromyalgia |
|
|
|
|
|
Thermo
Fisher Scientific Launches Comprehensive Online Metabolomics Resource
Center |
|
|
|
|
06/13/08 |
Novartis:
Higher initial dose of Glivec achieved better early responses than
standard dose for patients with chronic myeloid leukemia |
|
|
|
|
|
Roche:
New data reveals
Actemra is the first and only biologic drug to show superiority over
current standard of care in rheumatoid arthritis |
|
|
|
|
|
GSK:
US FDA approves Requip® XL™, the first and only oral once-daily
non-ergot dopamine agonist for Parkinson’s disease |
|
|
|
|
|
Data Show that Abbott's HUMIRA® (adalimumab) Reduced the Signs and
Symptoms of Ankylosing Spondylitis Up to Three Years |
|
|
|
|
06/12/08 |
Geron
Presents Data at ISSCR Showing That Its Embryonic Stem Cell Therapeutic
for Heart Failure Evades Direct Attack by the Human Immune System |
|
|
|
|
|
Invitrogen and Applied Biosystems to Combine |
|
|
|
|
06/11/08 |
Myriad Genetics'
Alzheimer's Disease Drug Mechanism of Action Detailed in Nature Article |
|
|
|
|
|
Genentech Settles Dispute Related To Cabilly Patent |
|
|
|
|
06/10/08 |
Roche moves
investigational diabetes drug, Taspoglutide, into Phase III clinical
trials |
|
|
|
|
06/4/08 |
MDS:
Scientific Collaboration Seeks to Develop New Methods to Better Identify
Contaminants in Drinking Water |
|
|
|
|
06/2/08 |
Thermo Fisher Scientific Strengthens Presence in India with Acquisition
of Chemito Technologies |
|
|
|
|
|
Agilent Technologies Introduces Triple Quadrupole GC/MS, Updated Triple
Quadrupole LC/MS at American Society for Mass Spectrometry |
|
|
|
|
|
Nonlinear dynamics to distribute
GeneBio’s Phenyx worldwide |
|
|
|
|
05/31/08 |
Roche:
Study confirms that
Avastin significantly increases chance of living without disease
progression in metastatic breast cancer |
|
|
|
|
05/30/08 |
Roche:
Continuing Herceptin
treatment prevents disease progression in women with aggressive
metastatic breast cancer |
|
|
|
|
|
|
|
05/29/08 |
Geneva Bioinformatics (GeneBio) SA
and Protagen AG today announced a distribution agreement that allows
GeneBio to distribute Protagen’s Modiro, a novel software tool enabling
rapid and automated detection of true post-translational modifications
in MS/MS datasets. |
|
|
|
|
|
Thermo Fisher Scientific to Showcase New Mass Spectrometry Systems,
Software and Workflow Solutions at ASMS 2008 |
|
|
|
|
05/28/08 |
GeneBio Announces New Addition to
its MS Platform Solutions - SmileMS : SmileMS is a unique software
platform for the identification and analysis of small molecules by mass
spectrometry. |
|
|
|
|
|
Novartis:
Extavia® approved in European Union for treatment of multiple sclerosis,
first in planned portfolio of therapies from Novartis |
|
|
|
|
05/20/08 |
Biotech could run into a rough patch, link to article at The San
Francisco Chronicle |
|
|
|
|
05/19/08 |
Profits elusive, but biotech still lures investors, link to article
at The San Francisco Chronicle |
|
|
|
|
|
GSK:
First pre-pandemic vaccine approved to help protect against pandemic
influenza |
|
|
|
|
05/16/08 |
Thermo Fisher Scientific Names Marc N. Casper as Chief Operating Officer |
|
|
|
|
|
Millenium:
New Data Support High Complete Remission Rates With VELCADE® (Bortezomib)
For Injection Based Therapies In Patients With Newly Diagnosed Multiple
Myeloma |
|
|
|
|
05/15/08 |
GE Healthcare to Distribute
GeneBio’s Phenyx in Latin America |
|
|
|
|
05/14/08 |
Takeda Completes Acquisition of Millennium |
|
|
|
|
05/09/08 |
Roche:
Actemra inhibits joint
damage and improves physical function of patients with Rheumatoid
Arthritis |
|
|
|
|
|
Takeda Successfully Completes Tender Offer for Millennium
Pharmaceuticals, Inc. and Announces Subsequent Offering Period |
|
|
|
|
|
Applera
Corporation's Board of Directors Formally Approves Proposed Separation
of Its Celera Business |
|
|
|
|
05/06/08 |
|
|
|
|
|
|
Geron:
University of
Edinburgh Human Embryonic Stem Cell Program Awarded UK Grant Funding |
|
|
|
|
04/29/08 |
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III
Clinical Study of RITUXAN in Systemic Lupus Erythematosus |
|
|
|
|
|
Compugen Announces Discovery of Blood Based Biomarker for Diagnosis of
Lung Cancer |
|
|
|
|
|
Takeda and Millennium Announce Early Termination of Hart-Scott-Rodino
Waiting Period |
|
|
|
|
04/28/08 |
Breakthrough technique pioneered at Novartis research institute restores
light sensitivity in damaged retinas |
|
|
|
|
04/25/08 |
Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of
Ipilimumab |
|
|
|
|
|
GSK receives positive opinion for conditional approval of new oral
breast cancer treatment, Tyverb (lapatinib) |
|
|
|
|
04/24/08 |
High court slashes $200 million from Genetech judgment |
|
|
|
|
|
Amgen first-quarter profit is nearly flat on declining sales |
|
|
|
|
|
BMS:
Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight
First Quarter for Bristol-Myers Squibb Company |
|
|
|
|
|
Thermo Fisher Scientific Reports Record 2008 First Quarter Revenues and
Operating Performance |
|
|
|
|
04/23/08 |
Novartis announces 20% average reduction in price of malaria drug
Coartem® to further accelerate access in malaria-endemic regions |
|
|
|
|
04/21/08 |
Novartis reports higher sales and earnings in first quarter of 2008
showing healthcare portfolio well on the way to new growth cycle |
|
|
|
|
04/20/08 |
Genentech Provides Update on "AVAiL" Phase III Study of Avastin Plus
Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung
Cancer |
|
|
|
|
04/17/08 |
Bristol-Myers Squibb to Announce Results for the First Quarter of 2008
on April 24 |
|
|
|
|
04/17/08 |
Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter
and Reaffirms Full-Year Growth Outlook |
|
|
|
|
|
Abbott Announces HUMIRA® (adalimumab) Approved in Japan for the
Treatment of Rheumatoid Arthritis |
|
|
|
|
04/15/08 |
Roche fully acquires
privately-owned biotech company Piramed |
|
|
|
|
04/14/08 |
Genentech and Biogen Idec Announce Top-Line Results From a Phase II/III
Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis |
|
|
|
|
04/11/08 |
Novartis
ASA404, a novel cancer agent, begins pivotal trial to explore new
approach in treating lung cancer, the leading cause of cancer death |
|
|
|
|
|
Lilly:
ALIMTA® (pemetrexed for injection) Receives European Approval for
Histologically-Based Use in First-Line Treatment of Most Common Lung
Cancer |
|
|
|
|
|
Vermillion Announces Issuance of U.S. Patent Covering the Discovery of
Novel Forms of Brain Natriuretic Peptide |
|
|
|
|
04/10/08 |
Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash
Tender Offer Valued at $8.8 Billion |
|
|
|
|
04/08/08 |
Novartis:
ACZ885, a new biological drug in development, shows potential in
treating serious life-long autoinflammatory diseases |
|
|
|
|
04/07/08 |
Thermo Fisher Scientific Introduces New Catalog for China |
|
|
|
|
|
Novartis to further strengthen its healthcare portfolio by acquiring 25%
stake in Alcon |
|
|
|
|
04/04/08 |
GSK:
FDA approves Rotarix [Rotavirus Vaccine, live, oral], the first vaccine
licensed to complete the rotavirus immunisation series by four months of
age |
|
|
|
|
04/03/08 |
Thermo Fisher Scientific Receives FDA Clearance for MRSA Test Medium |
|
|
|
|
|
Medarex Announces Ipilimumab Program Continues to Move Forward |
|
|
|
|
04/02/08 |
Amgen:
Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple
Skeletal Sites in Early and Later Stage Postmenopausal Women |
|
|
|
|
03/24/08 |
BMS:
BARACLUDE® (entecavir) Data Continue to Demonstrate Low Incidence of
Resistance Through Five Years of Treatment in Nucleoside-naive Chronic
Hepatitis B Patients
- Data Indicate Pre-existing Lamivudine Resistance Predisposes Patients
to Higher Rates of BARACLUDE Resistance |
|
|
|
|
|
Biogen Idec:
Researchers Report Neublastin Virtually Restores Complete Long-Term
Sensory Motor Function in Preclinical Studies |
|
|
|
|
03/20/08 |
Medarex Receives Milestone Payment for Submission of Regulatory
Application Requesting Approval of Golimumab (CNTO 148) in Europe for
the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and
Ankylosing Spondylitis |
|
|
|
|
03/19/08 |
Merck:
Supplemental Application for GARDASIL®, Merck's Cervical Cancer Vaccine,
Designated Priority Review by the U.S. FDA for Use in Women 27 through
45 |
|
|
|
|
03/17/08 |
Millennium Expands IBD Franchise with Addition of New Development
Candidate |
|
|
|
|
|
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for
Enbrel(R) |
|
|
|
|
03/13/08 |
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For
Injection Based Therapy As a Standard of Care In Newly Diagnosed
Multiple Myeloma Patients |
|
|
|
|
03/11/08 |
Geron:U.S.
Patent Office Upholds Two Additional Human Embryonic Stem Cell Patents
in Reexamination Decisions |
|
|
|
|
03/10/08 |
Novartis:
Femara® helps protect against return of breast cancer even when
treatment starts several years after completing tamoxifen therapy |
|
|
|
|
03/07/08 |
Lilly Announces Termination of AIR Insulin Program |
|
|
|
|
03/06/08 |
Thermo
Fisher Scientific Extends LTQ Orbitrap Mass Spectrometry Performance in
Proteomics with ETD and MALDI Capabilities |
|
|
|
|
|
Merck's ISENTRESS® (raltegravir) Tablets in Combination with other
Anti-HIV Medicines Maintained Reductions in HIV-1 Viral Load and
Increased CD4 Cell Counts Through 48 Weeks of Therapy in
Treatment-Experienced Adults |
|
|
|
|
03/03/08 |
Thermo Fisher Scientific Showcases Product Innovation at PITTCON 2008 |
|
|
|
|
|
GSK:
FDA grants Priority Review For Promacta / Revolade (Eltrombopag),
eltrombopag would be the first oral thrombopoeitin (TPO) receptor
agonist |
|
|
|
|
02/29/08 |
Roche:
Herceptin approved in
Japan for early treatment in patients with HER2-positive breast cancer |
|
|
|
|
|
Update on GSK's malaria treatments: Dacart and Lapdap |
|
|
|
|
02/28/08 |
Novartis:
Everolimus (RAD001) significantly extends progression-free survival in
advanced kidney cancer patients after failure of other targeted therapy |
|
|
|
|
02/23/08 |
FDA approves Avastin to treat breast cancer , link to
article at The San Francisco Chronicle |
|
|
|
|
|
Roche:
FDA grants accelerated
approval of Avastin in combination with paclitaxel chemotherapy for
first-line treatment of patients with advanced HER2-negative breast
cancer |
|
|
|
|
02/18/08 |
Thermo Scientific LTQ Orbitrap™
Mass Spectrometer Selected for Ground-Breaking Research in Disease
Treatment and Prevention |
|
|
|
|
02/08/08 |
GeneBio Announced the Release of
Version 7.0 of the Renowned Melanie 2-D Gel Analysis Platform. |
|
|
|
|
02/06/08 |
Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and
Operating Performance; Provides Guidance for 2008 |
|
|
|
|
|
GSK:
GlaxoSmithKline responds to findings in ACCORD study |
|
|
|
|
|
Lilly:
FDA Advisory Committee Supports Efficacy and Safety of Zyprexa®
Long-Acting Injection (LAI) for Schizophrenia Treatment |
|
|
|
|
|
BMS:
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ® (atazanavir
sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in
Previously Untreated HIV-Infected Adult Patients
Data also showed differences in gastrointestinal and lipid effects
between REYATAZ/ritonavir and lopinavir/ritonavir among study population |
|
|
|
|
|
Amgen:
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13
Amgen Clinical Candidates |
|
|
|
|
|
Applied Biosystems Expands Line of Labeling Chemistry Reagents to Help
Improve Proteomics Research |
|
|
|
|
02/05/08 |
Geron’s Second U.S.
Patent for Production of Pancreatic Islets From Human Embryonic Stem
Cells Strengthens Company’s Intellectual Property Position |
|
|
|
|
02/01/08 |
Novartis:
Galvus®, a new treatment for patients with type 2 diabetes, receives
European approval for label update paving the way for EU launches |
|
|
|
|
|
Amgen:
New Findings Show Enbrel(R) (etanercept) Significantly Reduced Levels of
C-Reactive Protein, a Marker of Inflammation, in Patients with Moderate
to Severe Plaque Psoriasis |
|
|
|
|
01/31/08 |
Research Using Thermo Fisher Scientific RNA-Interference Technology
Unveils Potential New Targets for HIV Drugs |
|
|
|
|
01/30/08 |
Millenium:
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In
Patients with Newly Diagnosed Multiple Myeloma |
|
|
|
|
|
Roche:
Record operating
results for Roche again in 2007 |
|
|
|
|
01/29/08 |
Thermo Fisher Scientific to Present at the 2008 Merrill Lynch Global
Pharmaceutical, Biotechnology & Medical Device Conference |
|
|
|
|
|
Myriad Genetics
Announces Completion of Phase 1 Trial of Anti-Thrombin Drug MPC-0920 |
|
|
|
|
|
Merck:
FDA Approves EMEND® (fosaprepitant dimeglumine) for Injection, Merck's
New Intravenous Therapy, for Use in Combination with Other Antiemetics
for Prevention of Nausea and Vomiting Caused by Chemotherapy |
|
|
|
|
|
CuraGen Corporation Receives Notification from NASDAQ |
|
|
|
|
01/28/08 |
Avastin receives broad
label extension in Europe for the treatment of patients with metastatic
colorectal cancer |
|
|
|
|
01/24/08 |
Genentech and Biogen Idec Announce Positive Results from a Phase III
Trial of Rituxan in Patients With Rheumatoid Arthritis Who Inadequately
Responded to Methotrexate |
|
|
|
|
01/21/08 |
Novartis:
Tekturna HCT®, a single-tablet combination of Tekturna®* and a diuretic,
receives US approval for treatment of high blood pressure |
|
|
|
|
01/19/08 |
VC Investments Rise to Six-Year High, link to article at The San
Francisco Chronicle |
|
|
|
|
01/18/08 |
Human embryos created from skin - Personalized stem cells are aim of
work, La Jolla firm says, link to article at The San Francisco
Chronicle |
|
|
|
|
|
Roche invests 430
million Swiss francs at sites in Germany and Switzerland |
|
|
|
|
|
Bristol-Myers Squibb Announces Closing of Its Barceloneta, Puerto Rico
Plant |
|
|
|
|
|
Abbott's HUMIRA® (adalimumab) Receives FDA Approval for Moderate to
Severe Chronic Plaque Psoriasis |
|
|
|
|
01/17/08 |
Novartis achieves record results in 2007 underscoring benefits of
strategic healthcare portfolio |
|
|
|
|
01/16/08 |
GeneBio's Phenyx Tapped by Chinese
State Key Laboratory of Proteomics |
|
|
|
|
01/15/08 |
GlaxoSmithKline and XenoPort report positive top-line results of second
phase 3 restless legs syndrome trial for XP13512/GSK1838262 |
|
|
|
|
01/08/08 |
Medarex Announces Allowance of Investigational New Drug Application for
Wholly Owned Fully Human Anti-CD70 Antibody, MDX-1411 |
|
|
|
|
|
Lilly:
FDA Approves Cialis® (tadalafil) for Once Daily Use for the Treatment of
Erectile Dysfunction |
|
|
|
|
|
Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb
Medical Imaging |
|
|
|
|
|
Biogen
Idec and PDL BioPharma License the Rights to Develop Volociximab in
Ophthalmic Indications to Ophthotech |
|
|
|
|
01/04/08 |
Millennium Announces 2008 Goals for Growth, Building on Record 2007
Results |
|
|
|
|
01/03/08 |
GlaxoSmithKline and Theravance announce start of large Phase 2B ICS and
LABA studies for asthma in the Horizon programme |
|
|
|
|
|
Bruker AXS Announces Agreement to Acquire Elemental Analysis Company
JUWE Laborgeraete GmbH |
|
|
|
|
12/20/07 |
Thermo Fisher Scientific Acquires Leading Chromatography Consumables
Provider, La-Pha-Pack |
|
|
|
|
|
CuraGen Corporation Announces Appointment of Sean Cassidy as CFO |
|
|
|
|
12/19/07 |
Applied Biosystems Promotes Mark Stevenson to President and Chief
Operating Officer |
|
|
|
|
|
Roche:
Avastin approved in
Europe for first-line treatment of patients with advanced kidney cancer |
|
|
|
|
|
CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II
Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma |
|
|
|
|
|
Biogen
Idec Announces First Startup in its Innovation Incubator |
|
|
|
|
12/17/07 |
GlaxoSmithKline receives FDA ‘complete response’ letter for cervical
cancer vaccine |
|
|
|
|
|
BMS:
Avista Capital Partners Agrees to Acquire Bristol-Myers Squibb Medical
Imaging for Approximately $525 Million |
|
|
|
|
12/16/07 |
GlaxoSmithKline announces data on Tykerb ® (lapatinib) plus capecitabine
for the treatment of HER2-positive breast cancer brain metastases
|
|
|
|
|
12/13/07 |
Biogen Says It Plans to Stay Independent, link to
article at The San Francisco Chronicle |
|
|
|
|
12/12/07 |
Geron Receives
Milestone Payment From Merck Triggered by IND Filing for Telomerase
Cancer Vaccine Candidate |
|
|
|
|
|
Biogen
Idec Completes Review of Strategic Alternatives, Company to Remain
Independent |
|
|
|
|
12/10/07 |
GlaxoSmithKline and OncoMed Pharmaceuticals form strategic alliance to
develop cancer stem cell antibody therapeutics |
|
|
|
|
12/09/07 |
Novartis:
New data show Glivec® halts progression to advanced stages of
life-threatening form of leukemia in sixth year of treatment |
|
|
|
|
|
Millenium:
Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic
Fourfold Increase in Complete Remission Rates When Combined With the
Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma |
|
|
|
|
12/08/07 |
Amgen:
Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets
Primary Endpoints |
|
|
|
|
12/05/07 |
Genentech Provides Update From Avastin FDA Advisory Meeting |
|
|
|
|
12/04/07 |
Myriad Genetics
Submits IND on Vivecon |
|
|
|
|
12/03/07 |
Thermo Fisher Scientific Selected by China Doping Control Center to
Supply Testing Instrumentation for the 2008 Olympic Games in Beijing |
|
|
|
|
|
Merck's ROTATEQ® Reduced Hospitalizations and Emergency Department
Visits Due to G9P1A[8] Rotavirus by 100 Percent as Shown by Post-hoc
Analysis of Data |
|
|
|
|
|
GSK response to Nature Medicine article on rosiglitazone and bone in
mice |
|
|
|
|
|
Caliper Life Sciences Introduces Drug Combination Services to Identify
Synergistic Response of Compounds |
|
|
|
|
12/02/07 |
Novartis further strengthens biologics capabilities in expansion of
MorphoSys collaboration |
|
|
|
|
11/30/07 |
Lilly:
FDA Approves Cymbalta® for Maintenance Treatment of Major Depressive
Disorder |
|
|
|
|
|
Bristol-Myers Squibb Joins with NJ Children's Hospital in Launching New
Center for Immune System Disorders and Infectious Diseases Including
HIV/AIDS |
|
|
|
|
|
Amgen Announces Interim Results of Aranesp(R) ''PREPARE'' Study in
Breast Cancer Patients |
|
|
|
|
11/25/07 |
Thermo Fisher Scientific Reports Record Third Quarter Revenues and
Adjusted EPS and Raises Full-Year Guidance |
|
|
|
|
11/23/07 |
Thermo Fisher Scientific Expands Clinical Trial Services Capabilities
with New Facility in India |
|
|
|
|
11/22/07 |
Thermo Fisher Scientific Advances Gene-Silencing Technology for Life
Sciences Research |
|
|
|
|
|
GSK:
New data published in The Lancet show GSK’s rotavirus vaccine Rotarix®
offers sustained and broad protection against all common circulating
rotavirus types |
|
|
|
|
11/21/07 |
Roche Submits
Application for FDA Approval of Actemra for the Treatment of Rheumatoid
Arthritis |
|
|
|
|
|
GlaxoSmithKline to acquire Reliant Pharmaceuticals |
|
|
|
|
|
Geron:
Recent Advances in
Cellular Reprogramming |
|
|
|
|
11/20/07 |
Drug Firms Cool to Stem Cell Findings, link to
article at The San Francisco Chronicle |
|
|
|
|
|
Mountain View startup offers DNA scans online, link to
article at The San Francisco Chronicle |
|
|
|
|
|
Genentech:
Avastin Shows Encouraging Results in Phase II Study in Patients With the
Most Aggressive Form of Brain Cancer |
|
|
|
|
|
BMS:
U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) as
the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
- ABILIFY Used With Another Antidepressant Can Help Adults Living With
Depression Who Have Failed to Achieve Adequate Symptom Relief -1 |
|
|
|
|
|
Biogen
Idec and Neurimmune Therapeutics Announce Alliance to Develop Treatments
for Alzheimer's Disease |
|
|
|
|
11/19/07 |
CVT:
FDA Accepts Ranexa(R) sNDA and NDA for Filing |
|
|
|
|
|
BMS:
Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients
Supports FDA Approval of AVALIDE® (irbesartan-hydrochlorothiazide)
as the First Combination Therapy for Initial Use in Patients Likely to
Need Multiple Drugs to Achieve Their Blood Pressure Goals |
|
|
|
|
|
Bayer:
Nexavar® First FDA-Approved Drug Therapy for Liver Cancer
Only Systemic Therapy Proven to Significantly Improve Overall Survival
in Patients with Liver Cancer |
|
|
|
|
11/18/07 |
Bruker Companies Announce the Opening of a Modern Chinese Applications,
Demonstration and Customer Training Center in Beijing |
|
|
|
|
11/16/07 |
Roche:
Avastin receives
positive opinion in Europe for first-line treatment of patients with
advanced kidney cancer |
|
|
|
|
|
BI:
CHMP
Adopts Negative Opinion on Appeal on European Application for
Natalizumab for The Treatment of Crohn's Disease |
|
|
|
|
|
Abbott's HUMIRA® Receives Positive Opinion from EMEA for Treatment of
Moderate to Severe Plaque Psoriasis |
|
|
|
|
11/15/07 |
PerkinElmer Completes Acquisition of ViaCell |
|
|
|
|
|
FDA approves Mircera:
first renal anemia treatment in the US with monthly maintenance dosing |
|
|
|
|
|
Novartis:
New data for Menveo(TM) vaccine show excellent immune response and broad
protection for infants against meningococcal meningitis |
|
|
|
|
11/14/07 |
Thermo Fisher Scientific
Launches MetWorks™ 1.1.0 |
|
|
|
|
|
Lilly:
FORTEO® Increased Spine Bone Mineral Density in Patients with
Glucocorticoid-Induced Osteoporosis |
|
|
|
|
11/13/07 |
Thermo Fisher Scientific Partners with Phytronix Technologies to Offer
Ultra High-Speed LDTD Technology for Large Volume LC/MS Analyses |
|
|
|
|
11/12/07 |
Abbott Receives U.S. Food and Drug Administration Approval for New
Lower-Strength Kaletra® (lopinavir/ritonavir) Tablet for Pediatric HIV
Patients |
|
|
|
|
11/08/07 |
CV Therapeutics' Selective Adenosine A1 Agonist Tecadenoson Shows
Synergistic Effect with Ultra Low Dose Beta Blocker in Preclinical
Atrial Fibrillation Model |
|
|
|
|
|
Amgen to Provide New Evidence as Part of a Formal Reconsideration of
CMS' National Coverage Determination on ESAs |
|
|
|
|
11/07/07 |
New South S.F. center to help Pfizer find next biotech cure, link to
article at The San Francisco Chronicle |
|
|
|
|
|
Amgen:
New Data Show That Half of Patients with Active Early Rheumatoid
Arthritis Achieved Clinical Remission at One Year When Treated with
Enbrel(R) (etanercept) Plus Methotrexate |
|
|
|
|
11/06/07 |
BMS:
U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for
Adolescent Patients with Schizophrenia
- Otsuka-sponsored Study Supported Efficacy, Safety and Tolerability of
ABILIFY in Pediatric Patients Ages 13-17 with Schizophrenia - |
|
|
|
|
11/05/07 |
GlaxoSmithKline initiates trials of Promacta®/Revolade™ (eltrombopag) to
investigate the potential to aid hepatitis C patients in achieving
sustained virological response |
|
|
|
|
|
CVT:
Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent
Ischemia in MERLIN TIMI-36 Patients With Elevated BNP |
|
|
|
|
11/02/07 |
Roche:
Treatment with Pegasys
provides hepatitis C patients a second chance to achieve a cure after
not responding to Peg-Intron |
|
|
|
|
|
Lilly:
Ninety-one Percent of BARACLUDE® (entecavir) Treated Patients in a
Four-Year Cohort Demonstrated Hepatitis B Virologic Suppression to
Undetectable Levels |
|
|
|
|
11/01/07 |
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R)
(Bortezomib) for Injection Sales |
|
|
|
|
|
Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of
Pain and Cognition |
|
|
|
|
10/30/07 |
MDS Pharma Services Expands Central Lab Operations in China |
|
|
|
|
|
Genentech revisits plan for Avastin, link to article at The San
Francisco Chronicle |
|
|
|
|
10/23/07 |
Emeryville biofuels crib to see how plants can fuel vehicles, link
to article at The San Francisco Chronicle |
|
|
|
|
|
Thermo Fisher Scientific Expands Clinical Trial Services Capabilities
with New Facility in India |
|
|
|
|
10/22/07 |
Thermo Fisher Scientific Advances Gene-Silencing Technology for Life
Sciences Research |
|
|
|
|
10/19/07 |
Roche:European
licence for Roche HIV drug Viracept re-established by European
Commission |
|
|
|
|
|
Roche:Pivotal
Mircera study first to convert dialysis patients from frequent dosing
directly to once every four weeks |
|
|
|
|
10/18/07 |
Bruker Companies Announce the Opening of a Modern Chinese Applications,
Demonstration and Customer Training Center in Beijing |
|
|
|
|
|
Abbott Scientists Create One Molecule With Two Antibody Functions
|
|
|
|
|
10/17/07 |
GSK:
New Lancet study: Malaria vaccine candidate has promising safety,
tolerability profile in infants |
|
|
|
|
10/16/07 |
Competition, market saturation may slow Genentech earns growth, link
to article at The San Francisco Chronicle |
|
|
|
|
|
AB:
Scientists Discover New Molecular Markers For Testicular Cancer |
|
|
|
|
10/15/07 |
AB
New Forensic Toxicology Application from Applied Biosystems/MDS SCIEX
Improves Accuracy of Screening for Drugs of Abuse |
|
|
|
|
10/12/07 |
Merck:
FDA Approves ISENTRESS™ (raltegravir) Tablets, First-in-Class Oral HIV-1
Integrase Inhibitor |
|
|
|
|
|
Genentech blocks eye doctors' supply channel to unapproved drug,
link to article at The San Francisco Chronicle |
|
|
|
|
|
PE:
PerkinElmer Commences Cash Tender Offer for ViaCell |
|
|
|
|
|
Biogen Idec:
Board of
Directors has authorized management to evaluate whether third parties
would have an interest in acquiring the Company at a price and on terms
that would represent a better value for its stockholders |
|
|
|
|
|
Biogen Idec:
Phase 2
Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in
Patients Receiving Interferon Beta Therapy |
|
|
|
|
10/11/07 |
PE:
PerkinElmer Responds to Food Contamination Crisis with Innovative
Melamine Analyzer |
|
|
|
|
10/09/07 |
Thermo Fisher Scientific Acquires Leader in Micro-Volume
Spectrophotometers, NanoDrop Technologies |
|
|
|
|
10/08/07 |
PE:
PerkinElmer Introduces Enhanced Protein Analysis and Imaging Portfolio |
|
|
|
|
10/04/07 |
GeneBio announces the release of
Phenyx version 2.5 |
|
|
|
|
10/02/07 |
BMS:Survival
Data In FDA Approval For ERBITUX® (Cetuximab) Supports Use As A Single
Agent In Patients With Advanced Colorectal Cancer |
|
|
|
|
|
GSK applies for licence to market OTC weight loss product In Europe
|
|
|
|
|
10/01/07 |
Applied Biosystems Announces Co-Development Agreement with Olink
Bioscience |
|
|
|
|
9/20/07 |
GeneBio and the SIB Launch an
Extended Version of Aldente, SIB's Peptide
Mass Fingerprint Tool |
|
|
|
|
|
The Proteomics Research
Group (PRG) of the Association of Biomolecular Resource Facilities
(ABRF) would like to invite you to participate in a study that explores
the use of different approaches for determining qualitative differences
between two similar samples. |
|
|
|
|
09/18/07 |
Millenium:
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped
Early Due to Highly Significant Efficacy Advantage of VELCADE(R)
(Bortezomib) for Injection Based Therapy Across All Endpoints |
|
|
|
|
|
Merck:
One-Year Data Showed Investigational Use of Initial Combination Therapy
with JANUVIA™ (sitagliptin) and Metformin Significantly Improved Blood
Sugar Control in Patients with Type 2 Diabetes Compared to Metformin
Alone |
|
|
|
|
09/17/07 |
Sanofi-Aventis Developing New Drugs, link to article at The San
Francisco Chronicle |
|
|
|
|
|
Celera and
Collaborators Identify Gene Variants Predicting Susceptibility to, and
Severity of, Rheumatoid Arthritis |
|
|
|
|
09/14/07 |
FDA Approves Lilly's Osteoporosis Drug EVISTA® (raloxifene HCl) to
Reduce The Risk of Invasive Breast Cancer in Two Populations of
Postmenopausal Women |
|
|
|
|
|
Bruker Daltonics Announces Contract Award for Phase III of the ARFCAM
Program by the U.S. Department of Homeland Security |
|
|
|
|
09/13/07 |
Gene therapy death raises ethical issues, link to article at The San
Francisco Chronicle
|
|
|
|
|
|
GeneBio's Phenyx Integrated with
Institute for System Biology's TPP |
|
|
|
|
09/11/07 |
GlaxoSmithKline and Sepracor Inc. announce international alliance for
commercilisation of Lunivia |
|
|
|
|
09/07/07 |
Court Rules in Favor of Applied Biosystems in Patent Suit with Enzo
Biochem, Inc. |
|
|
|
|
09/05/07 |
Thermo Fisher Scientific Acquires Instrument Sales Business of Davis
Inotek |
|
|
|
|
|
Applied Biosystems Expands Portfolio of Services for Mass Spectrometry
Instrument Systems |
|
|
|
|
09/04/07 |
Applied Biosystems Announces Software Development Initiative for
Next-Generation Sequencing |
|
|
. |
|
|
. |
|
|
. |
